NVCR250117P21000
- 0.15
- 0.000.00%
Novocure Newsroom
Express News | Novocure Ltd - Appoints Ashley Cordova as CEO Effective Jan 1, 2025
NovoCure Shares Are Trading Higher After Piper Sandler Maintained an Overweight Rating on the Stock and Raised Its Price Target From $28 to $42.
Novocure Is Maintained at Overweight by Piper Sandler
NovoCure Analyst Ratings
Piper Sandler Maintains Novocure(NVCR.US) With Buy Rating, Raises Target Price to $42
Analysts Have Conflicting Sentiments on These Healthcare Companies: Sanofi (OtherSNYNF) and NovoCure (NVCR)
SoundHound, Asana And Victorias Secret Are Among Top 10 Mid Cap Gainers Last Week (Dec 2-Dec 6): Are The Others In Your Portfolio?
Why NovoCure Stock Was Winning Big This Week
Express News | Novocure Ltd : JP Morgan Raises Target Price to $29 From $19
A Quick Look at Today's Ratings for Novocure(NVCR.US), With a Forecast Between $30 to $40
Zai Lab, Novocure Announce PANOVA-3 Trial Met Primary Endpoint
U.S. Small Caps Close Mixed As Novocure Lead, Archer Aviation Lags
12 Health Care Stocks Moving In Monday's Pre-Market Session
Dow Dips 150 Points; ISM Manufacturing PMI Tops Estimates
Positive Outlook for NovoCure: Buy Rating Backed by Successful PANOVA-3 Trial and Promising Market Potential
Leerink Partners Adjusts NovoCure Price Target to $33 From $28, Maintains Outperform Rating
XPeng, NovoCure, Merus, Gap And Other Big Stocks Moving Higher On Monday
NovoCure Up Over 30%, on Pace for Largest Percent Increase Since January 2023 -- Data Talk
NovoCure's Tumor-Treating Electric Fields Shows Promise In Pancreatic Cancer Patients
US stocks fluctuate | Novocure surged about 42% at one point.
On December 2, Glonghui reported that medical devices manufacturer Novocure Ltd. (NVCR.US) initially surged about 42%, with the increase now narrowing to 26.8%, marking the largest intraday increase since January 2023. Recent research results indicate that the company's cancer treatment Tumor Treating Fields for pancreatic cancer has achieved its primary endpoint. (Glonghui)